Comment from Biohaven Pharmaceuticals, Inc.

Summary: Biohaven Pharmaceuticals, Inc. supports the draft guidance as a significant step toward enabling the development of individualized therapies for rare genetic conditions. They request additional clarity on defining "plausible mechanism," clarifying evidence of effectiveness, and incorporating more explicit patient-centered perspectives and regulatory flexibility.